Literature DB >> 9592182

Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: relation to the proliferation and progression.

W Yasui1, Y Kudo, K Naka, J Fujimoto, T Ue, H Yokozaki, E Tahara.   

Abstract

The expression of CD44 splice variant containing exon 14 (variant exon 9: CD44v9) was examined immunohistochemically in non-neoplastic mucosa, adenoma and adenocarcinoma of the stomach and analyzed the relation with the expression of Ki-67 antigen and p53 protein. In non-neoplastic gastric mucosa, basolateral membrane of the epithelial cells in the pyloric glands showed the expression of CD44v9. The epithelial cells in the intestinal metaplastic mucosa of the stomach sometimes expressed CD44v9. In the neoplastic lesions, the expression of CD44v9 was detected in 20% (34/170) of the adenomas and 28% (132/478) of the adenocarcinomas, respectively. The incidence of CD44v9 expression did not differ among histological type of gastric carcinoma. Twelve per cent of the adenocarcinomas showed strong expression of CD44v9, whereas non of the adenomas did. The incidence of CD44v9 expression was significantly higher in carcinomas invading into muscularis propria or the cases of stages 3 and 4 in comparison with that in carcinomas limited to submucosa or the stages 1 and 2 cases (p<0.05). The incidence of positive cases was higher in carcinomas with lymph node metastasis than those without metastasis (p<0.05). The expression of CD44v9 was significantly correlated with the expression of Ki-67 (p<0.05). It was also correlated with the expression of p53 protein in the tumor cells (p<0.01). These findings overall suggest that the expression of CD44v9 may be associated with the development as well as progression of the gastric carcinomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9592182     DOI: 10.3892/ijo.12.6.1253

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

1.  CD44 family proteins in gastric cancer: a meta-analysis and narrative review.

Authors:  Ying Wu; Zhi Li; Chenlu Zhang; Kai Yu; Zan Teng; Guoliang Zheng; Shuang Wang; Yunpeng Liu; Lei Cui; Xiaosong Yu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 2.  Gastric cancer stem cells: evidence, potential markers, and clinical implications.

Authors:  Daniel Brungs; Morteza Aghmesheh; Kara L Vine; Therese M Becker; Martin G Carolan; Marie Ranson
Journal:  J Gastroenterol       Date:  2015-10-01       Impact factor: 7.527

3.  Evaluation of the prognostic value and functional roles of CD44v6 in gastric cancer.

Authors:  Jian-Wei Xie; Peng-Chen Chen; Chao-Hui Zheng; Ping Li; Jia-Bin Wang; Jian-Xian Lin; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin; Yao Lin; Chang-Ming Huang
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-26       Impact factor: 4.553

4.  Effect of P-selectin monoclonal antibody on metastasis of gastric cancer and immune function.

Authors:  Jin-Lian Chen; Wei-Xiong Chen; Jin-Shui Zhu; Ni-Wei Chen; Tong Zhou; Ming Yao; Dong-Qing Zhang; Yun-Lin Wu
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

5.  Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation.

Authors:  Tomoko Jogo; Eiji Oki; Ryota Nakanishi; Koji Ando; Yuichiro Nakashima; Yasue Kimura; Hiroshi Saeki; Yoshinao Oda; Yoshihiko Maehara; Masaki Mori
Journal:  Gastric Cancer       Date:  2021-05-08       Impact factor: 7.370

6.  The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer.

Authors:  Byung Ik Jang; Yuan Li; David Y Graham; Putao Cen
Journal:  Gut Liver       Date:  2011-11-21       Impact factor: 4.519

7.  CD44 Variant 9 Serves as a Poor Prognostic Marker in Early Gastric Cancer, But Not in Advanced Gastric Cancer.

Authors:  Se-Il Go; Gyung Hyuck Ko; Won Sup Lee; Rock Bum Kim; Jeong-Hee Lee; Sang-Ho Jeong; Young-Joon Lee; Soon Chan Hong; Woo Song Ha
Journal:  Cancer Res Treat       Date:  2015-03-17       Impact factor: 4.679

8.  Metabolic Profiling of Human Gastric Cancer Cells Treated With Salazosulfapyridine.

Authors:  Kohei Takizawa; Koji Muramatsu; Kouji Maruyama; Kenichi Urakami; Takashi Sugino; Masatoshi Kusuhara; Ken Yamaguchi; Hiroyuki Ono; Yuko Kitagawa
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

9.  CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients.

Authors:  Zhonghu Li; Kai Chen; Peng Jiang; Xi Zhang; Xiaowu Li; Zhihua Li
Journal:  Diagn Pathol       Date:  2014-04-08       Impact factor: 2.644

10.  Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer.

Authors:  Hirokazu Kodama; Satoshi Murata; Mitsuaki Ishida; Hiroshi Yamamoto; Tsuyoshi Yamaguchi; Sachiko Kaida; Tohru Miyake; Katsushi Takebayashi; Ryoji Kushima; Masaji Tani
Journal:  Br J Cancer       Date:  2016-12-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.